Drug Trial Radar · NCT06211036
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
563
Actual
Start
Jun 5, 2024
Primary completion
Apr 2, 2030
Study completion Apr 2, 2030
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Jan 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS).
Conditions
- Extensive-Stage Small-Cell Lung Cancer
- Small-Cell Lung Cancer
Interventions
TarlatamabDrug
Intravenous (IV) infusion
DurvalumabDrug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- OSTime frame: Up to approximately 3 years
Locations
219 sites in 29 countries. Site status is shown where the registry gives one.
Infirmary Cancer Center
Mobile, Alabama
University of Southern California
Los Angeles, California
Yale New Haven Hospital
New Haven, Connecticut
University Cancer and Blood Center LLC
Athens, Georgia
Emory University
Atlanta, Georgia
Northeast Georgia Medical Center
Gainesville, Georgia
University of Illinois Chicago
Chicago, Illinois
Franciscan Health Indianapolis
Indianapolis, Indiana
Our Lady of the Lake Cancer Institute
Baton Rouge, Louisiana
Dana-Farber Cancer Institute
Boston, Massachusetts
Cancer and Hematology Centers of Western Michigan
Grand Rapids, Michigan
Mayo Clinic
Rochester, Minnesota
Allina Health System dba Allina Health Cancer Institute
Saint Paul, Minnesota
Oncology Hematology Associates
Springfield, Missouri
Nebraska Cancer Specialists
Omaha, Nebraska
Astera Cancer Care
East Brunswick, New Jersey
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey
Montefiore Medical Center - Bronx
The Bronx, New York
Duke University
Durham, North Carolina
Wake Forest University Health Sciences
Winston-Salem, North Carolina
Oncology Hematology Care Incorporated
Cincinnati, Ohio
University Hospitals Cleveland Medical Center
Cleveland, Ohio
The Ohio State University
Columbus, Ohio
Oncology Associates of Oregon, PC
Eugene, Oregon
Oregon Health and Science University
Portland, Oregon
Allegheny Health Network
Pittsburgh, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
Baptist Cancer Center Memphis Thoracic
Memphis, Tennessee
Sarah Cannon Research Institute
Nashville, Tennessee
Texas Oncology - Dallas Fort Worth
Dallas, Texas
US Oncology Research Investigational Products Center
Dallas, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas
Virginia Oncology Associates
Newport News, Virginia
Virginia Commonwealth University Massey Cancer Center
Richmond, Virginia
Swedish Cancer Institute
Seattle, Washington
The Medical College of Wisconsin
Milwaukee, Wisconsin
Fundacion Centro Oncológico Riojano Integral para la Investigación y Prevención del Cáncer
La Rioja, Argentina
Hospital Britanico de Buenos Aires
CABA, Buenos Aires, Argentina
Instituto Alexander Fleming
Capital Federal, Buenos Aires, Argentina
Showing 40 of 219 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.